MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes

Ross, 1999, Atherosclerosis—an inflammatory disease, N. Engl. J. Med., 340, 115, 10.1056/NEJM199901143400207 Hansson, 2005, Inflammation, atherosclerosis, and coronary artery disease, N. Engl. J. Med., 352, 1685, 10.1056/NEJMra043430 Beckman, 2002, Diabetes and atherosclerosis: epidemiology, pathophysiology, and management, JAMA, 287, 2570, 10.1001/jama.287.19.2570 Charo, 2006, The many roles of chemokines and chemokine receptors in inflammation, N. Engl. J. Med., 354, 610, 10.1056/NEJMra052723 Takeya, 1993, Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody, Hum. Pathol., 24, 534, 10.1016/0046-8177(93)90166-E Yla-Herttuala, 1991, Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions, Proc. Natl. Acad. Sci. U.S.A., 88, 5252, 10.1073/pnas.88.12.5252 Lu, 1998, Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice, J. Exp. Med., 187, 601, 10.1084/jem.187.4.601 Gu, 1998, Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice, Mol. Cell, 2, 275, 10.1016/S1097-2765(00)80139-2 Aiello, 1999, Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice, Arterioscler. Thromb. Vasc. Biol., 19, 1518, 10.1161/01.ATV.19.6.1518 Rovin, 1999, A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression, Biochem. Biophys. Res. Commun., 259, 344, 10.1006/bbrc.1999.0796 Kim, 2002, The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE, Am. J. Kidney Dis., 40, 1146, 10.1053/ajkd.2002.36858 Szalai, 2001, Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients, Atherosclerosis, 158, 233, 10.1016/S0021-9150(01)00423-3 McDermott, 2005, CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study, Circulation, 112, 1113, 10.1161/CIRCULATIONAHA.105.543579 Tabara, 2003, Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness, Hypertens. Res., 26, 677, 10.1291/hypres.26.677 O’Leary, 1999, Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults, N. Engl. J. Med., 340, 14, 10.1056/NEJM199901073400103 Blin, 1976, A general method for isolation of high molecular weight DNA from eukaryotes, Nucleic Acids Res., 3, 2303, 10.1093/nar/3.9.2303 Nelken, 1991, Monocyte chemoattractant protein-1 in human atheromatous plaques, J. Clin. Invest., 88, 1121, 10.1172/JCI115411 Martinovic, 2005, Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease, Circ. J., 69, 1484, 10.1253/circj.69.1484 Chiarelli, 2002, Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes, Diabetes Care, 25, 1829, 10.2337/diacare.25.10.1829 Banba, 2000, Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy, Kidney Int., 58, 684, 10.1046/j.1523-1755.2000.00214.x Morii, 2003, Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy, J. Diabetes Complications, 17, 11, 10.1016/S1056-8727(02)00176-9 Tashiro, 2002, Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy, J. Clin. Lab. Anal., 16, 1, 10.1002/jcla.2057 Gonzalez, 2002, HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels, Proc. Natl. Acad. Sci. U.S.A., 99, 13795, 10.1073/pnas.202357499 Cho, 2004, The MCP-1 promoter −2518 polymorphism in Behcet's disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients, Autoimmunity, 37, 77, 10.1080/08916930310001609446 Simeoni, 2004, Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and type 2 diabetes mellitus, Diabetologia, 47, 1574, 10.1007/s00125-004-1494-4 Zietz, 2005, Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the −2518 A→G promoter polymorphism, Diabetes Obes. Metab., 7, 570, 10.1111/j.1463-1326.2004.00436.x Inadera, 1999, Increase in circulating levels of monocyte chemoattractant protein-1 with aging, J. Interferon Cytokine Res., 19, 1179, 10.1089/107999099313127 Frazier-Jessen, 1995, Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages, J. Immunol., 154, 1838, 10.4049/jimmunol.154.4.1838 Pervin, 1998, Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 18, 1575, 10.1161/01.ATV.18.10.1575